Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Helsinn Investment Fund

Helsinn Investment Fund
VC INVESTOR TYPE
Active STATUS
11 INVESTMENTS
8 PORTFOLIO
2 EXITS
Description

Helsinn Investment Fund is the corporate venture arm of Helsinn Group. The firm focuses on privately-owned companies with early stage technologies in the oncology, biotechnology, pharmaceutical, medical devices and food supplements. It is based in Luxembourg, Luxembourg.

Investor Status
Actively Seeking New Investments
Year Founded
2016
Primary Investor Type
Corporate Venture Capital
Other Investor Types
Venture Capital
Primary Office
  • 412F, route d'Esch
  • Luxembourg, 2086
  • Luxembourg

Helsinn Investment Fund Investments (11)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Gain Therapeutics 19-Feb-2019 Early Stage VC 00.000 Drug Discovery Generating Revenue 00000000 0000000
0000 000000000000 12-Nov-2018 00000 00000 000.00 Drug Discovery Pre-Clinical Trials 00000000 0000000
000000000000 01-Aug-2018 00000 00000 0000 Biotechnology Generating Revenue
0000000000 30-Apr-2018 00000 00000 000 Biotechnology Generating Revenue 0000000 00 00000
00 000000 00000000 14-Mar-2018 00000 00000 0000 Other Healthcare Technology Systems Clinical Trials - Phase 2
00000000 000000 00 04-Jan-2018 00000 00000 0000 Biotechnology Generating Revenue
000000000 00000 16-Jun-2017 00000 00000 00.00 Other Devices and Supplies Product Development
0000 08-May-2017 00000 00000 0000 Biotechnology Clinical Trials - Phase 2
OncoResponse 23-Mar-2017 Early Stage VC 000.00 Biotechnology Generating Revenue
QuantuMDx 14-Dec-2016 Later Stage VC 000.00 Laboratory Services (Healthcare) Generating Revenue
To view this investor’s complete investment and acquisition history, request access »
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Helsinn Investment Fund’s full profile, request a free trial.

Helsinn Investment Fund Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
Amal Therapeutics 15-Jul-2019 Merger/Acquisition 00000 Completed
  • Boehringer Ingelheim
000 000000 000000000 00000000 Completed
To view this investor’s complete exits history, request access »

Helsinn Investment Fund Team (4)

Name Title Deals Funds Boards Office Contact
Info
Roberto De Ponti Advisor 0 Luxembourg, Luxembourg
Sandra van Essche JD Advisor and Consultant Luxembourg, Luxembourg
Hanna Kleczkowska Ph.D Principal Investment Advisor Luxembourg, Luxembourg
Karin Hehenberger Ph.D Advisor and Consultant 0 Luxembourg, Luxembourg